Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Avalo Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Avalo Therapeutics, Inc.

AVTX

Avalo Therapeutics, Inc.

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company developing therapies targeting immune dysregulation, with a focus on inflammatory diseases. Its lead product candidate, AVTX-009, is a humanized anti-IL-1β monoclonal antibody aimed at treating conditions like hidradenitis suppurativa. Avalo operates through clinical development, relying on third-party manufacturing and regulatory approvals, targeting global markets in dermatology, gastroenterology, and rheumatology with a focus on innovative biologic therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Avalo Therapeutics, Inc.

1
1
Avalo Therapeutics, Inc. Avalo Therapeutics Reports $19.6 Million Net Loss in Q1 2026, Plans Phase 3 Trials for Abdakibart

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Avalo Therapeutics, Inc. Avalo Therapeutics Reports $78.3 Million Net Loss and Focuses on Phase 2 LOTUS Trial

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Avalo Therapeutics, Inc. Avalo Therapeutics Reports No Product Revenue and $64.5 Million Net Loss for Quarter Ending September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Avalo Therapeutics, Inc. Avalo Therapeutics Reports $33.9 Million Net Loss and Increased R&D Expenses for First Half of 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Avalo Therapeutics, Inc. Avalo Therapeutics Reports $13.1 Million Net Loss in Q1 2025, Down from $121.3 Million Last Year

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Avalo Therapeutics, Inc. Avalo Therapeutics Reports $35.1 Million Net Loss for 2024, Highlights AlmataBio Acquisition

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Avalo Therapeutics, Inc. Avalo Therapeutics Reports Net Income Turnaround, Improved Cash Position, and Strategic Acquisitions in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments